Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential

OKYO Pharma Limited Sponsored ADR (OKYO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock and has a $7.00 price target.

Yi Chen’s rating is based on the promising potential of OKYO Pharma’s lead drug candidate, urcosimod, which has shown significant efficacy in treating dry eye disease (DED) by improving symptoms such as stinging, burning, and ocular pain. The drug’s dual action as an anti-inflammatory and pain-modulating agent further strengthens its therapeutic promise, particularly for neuropathic corneal pain (NCP), a condition lacking FDA-approved treatments.
The ongoing Phase 2a trial for urcosimod in NCP patients is another critical factor, with its successful results potentially opening up a new market for OKYO Pharma. The favorable safety and efficacy profile demonstrated in earlier trials adds confidence in its future success. Moreover, the valuation of OKYO Pharma at a $300 million market value, combined with a projected price target of $7 per share, supports the Buy recommendation, despite the risks associated with clinical trial outcomes and market competition.